Clinical trial · Interventional
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma
NCT00688415CI-TRIAL-00040815completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. The pharmacology of VTX-2337 will also be evaluated.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VTX-2337 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Safety and identification of dose-limiting toxicities
- timeFrame
- Study duration
- measure
- Pharmacokinetics
- timeFrame
- First dose of investigational drug
Secondary outcomes (2)
- measure
- Pharmacodynamics
- timeFrame
- Study duration
- measure
- Identification of the MTD
- timeFrame
- First cycle of investigational drug
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Other specific eligibility criteria may apply. Examination by the investigator is necessary to fully determine eligibility. Inclusion Criteria: * Ability and willingness to provide written informed consent * Histologically or cytologically confirmed solid tumors or lymphoma * Locally advanced or metastatic disease * Life expectancy of at least 16 weeks * ECOG performance status of 0 or 1 * Acceptable physical exam and laboratory tests at study entry * Willingness to use medically acceptable contraception * A negative serum pregnancy test for women with reproductive potential Exclusion Criteria: * Anticancer therapy within 2 weeks * Treatment with an investigational agent within 4 weeks * Systemic corticosteroids within 2 weeks or a requirement for systemic immunosuppressive therapy * Known brain metastases unless stable for at least 28 days * Active autoimmune disease * Insulin-dependent diabetes mellitus * Clinically significant cardiac disease within 6 months * Significant infection or fever within 1 week * Pregnant or breast-feeding females * Other conditions or circumstances that could interfere with the study
References
Publications (0)
Data not yet available
No reference posted for this study.